Various technologies are available to study the mutations that cause cancer, but none are capable of accurate detection of all types of genetic aberrations. By combining information from multiple technologies, researchers can analyse complex cancer samples and get the most complete overview of disease-driving mutations.
OGT offers an integrated portfolio of products providing clinical researchers with the most advanced tools available to study solid tumours, including CytoCell® fluorescence in-situ hybridisation (FISH) probes and myProbes® custom FISH probes, SureSeq™ Next Generation Sequencing (NGS) panels and myPanel™ custom panels, and CytoSure® array products and custom arrays. We partner with leading clinical researchers to advance discoveries by providing proven, high-quality solutions.
The HER2 amplification probe consists of a 347kb probe labelled in red, spanning the HER2 (ERBB2) gene and neighbouring regions, and a green probe for the chromosome 17 centromere.
View ProductThe ROS1 Breakapart probe consists of a green 406kb probe and two red 299kb and 171kb probes, which are positioned on each side of the ROS1 gene.
View ProductThe SureSeq Breast Cancer + CNV Panel has been developed to provide comprehensive coverage of 7 key genes implicated in breast and ovarian cancer, including BRCA1 and BRCA2. Detecting SNVs and indels, as well as exon-level to whole gene CNVs, provides researchers with a single NGS workflow to study clinically relevant aberrations and alleviates the burden of running multiple assays. The figure (above) illustrates the excellent coverage uniformity across BRCA1 exons 9, 10 and 11 [A] and BRCA2 exons 9, 10 and 11 [B].
View ProductChoose your perfect colorectal NGS panel from our range of fully tested and optimised panel content. Simply mix and match the genes or individual exons you require and get the most out of your sequencing runs. The figure (above) illustrates the excellent uniformity of coverage of BRAF exon 15 (top) and TP53 exons 3 - 9 (bottom).
View Product
